Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Accepted: 15 April 2026
First Online: 28 May 2026
Competing interests
: Y.N., S.M. and M.K. declare no competing interests. I.N. has received research funding from Astellas, Ono Pharmaceutical, Merck Sharp & Dohme, Daiichi Sankyo, Boehringer Ingelheim and Chugai Pharmaceutical. I.N. has received lecture fees from Astellas, Ono Pharmaceutical, Bristol Myers Squibb, Merck Sharp & Dohme, Daiichi Sankyo, Taiho Pharmaceutical and AstraZeneca outside the submitted work. I.N. has received honoraria for advisory board participation from AstraZeneca and Amgen.
